Evidence map›Paper›PMID 19766123›Full record

ArticleJournal of molecular biology2009

Reconstitution and engineering of apoptotic protein interactions on the bacterial cell surface.

Jingjing Sun, Diya M Abdeljabbar, Nicole Clarke, Meghan L Bellows, Christodoulos A Floudas, A James Link

Abstract read
In one paragraph

Article in Journal of molecular biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingjing SunDepartment of Chemical Engineering, Princeton University, Princeton, NJ 08544, USA.
Diya M Abdeljabbar
Nicole Clarke
Meghan L Bellows
Christodoulos A Floudas
A James Link

Funding

STRUCTURE PREDICTION OF PEPTIDES VIA GLOBAL OPTIMIZATIONR01GM052032 · NIGMS · PRINCETON UNIVERSITY · PI FLOUDAS, CHRISTODOULOS ACHILLEUS · 1996 to 2011
$1.9M
NIGMS NIH HHS R01 GM052032NIGMS NIH HHS R01 GM52032
6 · The paper itself

Abstract

The interactions between pro- and anti-apoptotic members of the Bcl-2 class of proteins control whether a cell lives or dies, and the study of these protein-protein interactions has been an area of intense research. In this report, we describe a new tool for the study and engineering of apoptotic protein interactions that is based on the flow cytometric detection of these interactions on the surface of Escherichia coli. After validation of the assay with the well-studied interaction between the Bak(72-87) peptide and the anti-apoptotic protein Bcl-x(L), the effect of both increasing and decreasing Bak peptide length on Bcl-x(L) binding was investigated. Previous work demonstrated that the Bak(72-87) peptide also binds to the anti-apoptotic protein Bcl-2, albeit with lower binding affinity compared to Bcl-x(L). Here, we demonstrate that a slightly longer Bak peptide corresponding to amino acids 72-89 of Bak binds Bcl-x(L) and Bcl-2 equally well. Approximate binding affinity calculations on these peptide-protein complexes confirm the experimental observations. The flow cytometric assay was also used to screen a saturation mutagenesis library of Bak(72-87) variants for improved affinity to Bcl-x(L). The best variants obtained from this library exhibit an apparent K(d) to Bcl-x(L) 4-fold lower than that of wild-type Bak(72-87).

Indexed as

ApoptosisAnimalsArgininebcl-2 Homologous Antagonist-Killer Proteinbcl-X ProteinCell MembraneEscherichia coliFlow CytometryHumansMutagenesisPeptidesProtein EngineeringTyrosineArgininebcl-2 Homologous Antagonist-Killer Proteinbcl-X ProteinPeptidesTyrosine

Identifiers

PMID19766123
PMCPMC2913173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.